Microbix Biosystms stock analysis
Want to see TSE:MBX full AI Analyst Report?
Microbix Biosystms (MBX) Stock Price & Analysis
MBX Stock Chart & Stats
- Day’s Range
- CAD 0.31 - CAD 0.31
- 52-Week Range
- CAD 0.21 - CAD 0.33
- Previous Close
- CAD 0.29
- Volume
- N/A
- Average Volume (3M)
- 25.26K
- Market Cap
- CAD 41.78M
- Enterprise Value
- CAD 40.83M
- Total Cash (Recent Filing)
- CAD 7.16M
- Total Debt (Recent Filing)
- CAD 6.72M
- Price to Earnings (P/E)
- ―
- Beta
- -0.14
- Next Earnings
- Dec 17, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth
Growth across core antigens, CAPs, and direct clinical-laboratory sales indicates broader commercial traction rather than reliance on one product line. A developing recurring B2C channel can improve revenue visibility and support scale over the next several quarters.
Process Efficiency
Higher yields and process improvements can reduce unit costs while increasing production capacity, supporting margin recovery as volumes expand. These operational capabilities may strengthen Microbix’s ability to serve diagnostic customers efficiently and improve operating leverage.
Manageable Leverage
Moderate leverage gives the company more financial flexibility than a heavily debt-funded business, despite current losses. A manageable debt burden can reduce balance-sheet pressure and preserve options to fund production scaling and commercial development.
Bears Say
Persistent Cash Burn
Negative operating and free cash flow show that the business is not currently funding itself internally. Continued cash consumption could constrain investment in production and commercialization, increase reliance on the cash balance, and delay the benefits of future revenue growth.
China Revenue Decline
The sharp and prolonged China revenue decline has reduced the company’s historical scale and demonstrates exposure to regional demand volatility. Even the targeted recovery would remain well below the former peak, limiting near-term revenue normalization and operating leverage.
Customer Timing Risk
Dependence on customer timelines makes revenue conversion less predictable, even when commercial discussions are progressing. Delayed contracts or validations can create uneven quarterly performance, complicate capacity planning, and prolong the period before fixed costs are absorbed.
Microbix Biosystms News
MBX FAQ
What was Microbix Biosystms’s price range in the past 12 months?
What is Microbix Biosystms’s market cap?
When is Microbix Biosystms’s upcoming earnings report date?
How were Microbix Biosystms’s earnings last quarter?
Is Microbix Biosystms overvalued?
Does Microbix Biosystms pay dividends?
What is Microbix Biosystms’s EPS estimate?
How many shares outstanding does Microbix Biosystms have?
What happened to Microbix Biosystms’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Microbix Biosystms?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Microbix Biosystms
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cameron L. Groome
- Employees
- 100
- Website
- microbix.com
- Address
- 265 Watline Avenue, Mississauga, ON, L4Z 1P3, CA
Microbix Biosystms (MBX) Earnings & Revenues
MBX Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful operational and commercial progress: double-digit YoY growth in Q3 (17%), strong up-ticks in antigen (+20%) and CAPs (+13%), margin improvement, tangible advances on the Kinlytic program (process breakthroughs, comparability work, planned FDA engagement) and accelerating direct end-user (B2C) sales (35% QoQ). Offsetting factors include a continuing net loss (~$800K for the quarter), the protracted recovery in China (down from prior peak to current six-figure levels), ongoing dependence on client timelines for large contracts, and limited orders in certain product lines (VTM/DxTM). Management is balancing share buybacks with cash preservation for scaling production. On balance, the call leaned positive due to clear revenue growth, margin improvement, operational efficiencies, and concrete progress toward regulatory milestones, albeit with remaining execution and market concentration risks.
View all TSE:MBX earnings summariesMBX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 5 |
| Technical Analysis | 5 | 4 | 1 |
| Moving Averages | 8 | 0 | 4 |
